|
Variables
|
N = 427
|
28-days
|
p value
|
|---|
|
Mortality N = 102
|
Survival N = 325
|
|---|
|
MI
| | | |
0.179
|
|
NSTEMI
|
121(28.3)
|
32(31.4)
|
89(27.4)
| |
|
AWSTEMI
|
126(29.5)
|
35(34.3)
|
91(28.0)
| |
|
NAWSTEMI
|
180(42.1)
|
35(34.3)
|
145(44.6)
| |
|
Age, years
|
66.9 ± 12.3
|
69.4 ± 13.3
|
66.2 ± 11.9
|
0.020
|
|
Male, n(%)
|
304(71.8)
|
69(67.6)
|
238(73.2)
|
0.274
|
|
BMI, kg/m2
|
28.0 ± 5.5
|
28.1 ± 5.9
|
27.9 ± 5.4
|
0.871
|
|
Past medical history
| | | | |
|
Hypertension, n(%)
|
55(12.9)
|
23(22.5)
|
32(9.8)
|
0.001
|
|
Diabetes, n(%)
|
138(32.3)
|
38(37.2)
|
100(30.8)
|
0.222
|
|
CHF, n(%)
|
49(11.5)
|
17(16.7)
|
32(9.8)
|
0.059
|
|
COPD, n(%)
|
77(1.6)
|
17(16.7)
|
60(18.5)
|
0.681
|
|
Peripheral, n(%)
|
70(1.6)
|
19(18.6)
|
51(15.7)
|
0.485
|
|
Heart rate, bpm
|
86.7 ± 14.5
|
89.6 ± 17.8
|
85.7 ± 13.2
|
0.019
|
|
MBP, mmHg
|
77.2 ± 8.1
|
75.3 ± 9.8
|
77.8 ± 7.4
|
0.007
|
|
SpO2, %
|
97.5 ± 2.2
|
96.7 ± 3.3
|
97.8 ± 1.6
|
0.000
|
|
*RASS score
|
0(− 2,0)
|
− 0.5(− 3,0)
|
0(− 1,0)
|
0.128
|
|
Biochemistry
| | | | |
|
WBC, K/uL
|
14.1 ± 7.1
|
16.8 ± 8.7
|
13.3 ± 6.4
|
0.000
|
|
PLT, K/uL
|
220.7 ± 99.0
|
223.4 ± 101.5
|
219.8 ± 98.3
|
0.753
|
|
HGB, g/dl
|
10.8 ± 2.0
|
10.7 ± 1.9
|
10.8 ± 2.1
|
0.788
|
|
TB, mg/dl
|
1.1 ± 2.5
|
1.7 ± 4.8
|
0.9 ± 0.7
|
0.008
|
|
Glu, mg/dl
|
181.8 ± 105.1
|
229.9 ± 122.7
|
166.6 ± 94.2
|
0.000
|
|
Scr, mg/dl
|
1.3 ± 1.2
|
1.7 ± 1.2
|
1.2 ± 1.2
|
0.000
|
|
Potassium, mEq/L
|
4.3 ± 0.7
|
4.3 ± 0.7
|
4.3 ± 0.7
|
0.995
|
|
&Serum tropoin, ng/ml
|
4.3 ± 0.5
|
7.6 ± 1.3
|
2.9 ± 0.3
|
0.000
|
|
Treatments
| | | | |
|
Aspirin, n(%)
|
323(75.6)
|
55(53.9)
|
268(82.5)
|
0.000
|
|
Clopidogrel, n(%)
|
142(33.3)
|
28(27.4)
|
114(35.1)
|
0.154
|
|
Betablock, n(%)
|
257(83.6)
|
58(56.9)
|
299(92.0)
|
0.000
|
|
Stain, n(%)
|
287(67.2)
|
41(40.2)
|
246(75.7)
|
0.000
|
|
Vasopressor, n(%)
|
335(78.5)
|
94(92.2)
|
241(74.2)
|
0.000
|
|
Mechanical ventilation, n(%)
|
399(93.4)
|
96(94.1)
|
303(93.2)
|
0.752
|
|
#Revascularization, n(%)
|
299(70.0)
|
47(46.1)
|
252(77.5)
|
0.000
|
|
Propofol, n(%)
|
272(63.7)
|
45(44.1)
|
227(69.8)
|
0.000
|
|
Midazolam, n(%)
|
143(33.5)
|
56(54.9)
|
87(26.8)
|
0.000
|
|
Dexmedetomidine, n(%)
|
28(6.5)
|
2(2.0)
|
26(8.0)
|
0.032
|
|
Propofol + Midazolam
|
53(12.4)
|
17(16.6)
|
36(11.1)
|
0.135
|
|
Propofol + Dexmedetomidine
|
22(5.1)
|
1(1.0)
|
21(6.5)
|
0.036
|
|
Midazolam + Dexmedetomidine
|
13(3.0)
|
1(1.0)
|
12(3.7)
|
0.318
|
|
All three seditives
|
8(1.9)
|
0(0)
|
8(2.5)
|
0.207
|
- MI myocardial infarction; NSTEMI non-ST segment elevated myocardial infarction; AWSTEMI anterior wall ST segment elevated myocardial infarction; NAWSTEMI non-anterior wall ST segment elevated myocardial infarction; BMI body mass index; CHF congestive heart failure; COPD chronic obstructive pulmonary disease; MBP mean arterial pressure; WBC white blood cell; PLT platelet; HGB hemoglobin; TB total bilirubin; Glu glucose; Scr creatinine; *, 141 patients with RASS scores records, include 40 patients in mortality group and 101 in survival group; & 289 patients with serum tropoin record, include 201 patients in mortality group and 88 in survival group; #, include percutaneous coronary intervention and coronary artery bridge graft
